ENTLEP001 - Obesity and Metabolic Disease

Despite recent advancements in the treatment of obesity, significant gaps remain including long-term compliance, GI side effects, loss of lean muscle mass, and weight maintenance.

ENTLEP001 is a gene therapy that leverages the Fusogenix PLV systemic formulation and encodes the leptin hormone. ENTLEP001 has demonstrated robust clinical effects and durability in relevant non-clinical models.

Leveraging leptin biology as the backbone and utilizing a genetic medicine approach to the treatment of obesity and metabolic diseases, ENTLEP001 is well positioned to:

• Achieve synergistic weight loss in combination with currently available and pipeline treatments that leverage the GLP-1 and amylin agonism pathways.
• Improve long-term compliance and therefore outcomes through once yearly dosing.
• Reduce the dose and/or frequency of synergistic anti-obesity therapies to decrease adverse events.
• Support weight maintenance as a monotherapy after the weight loss goal is achieved.

Our first clinical program for ENTLEP001 will target congenital generalized lipodystrophy to facilitate a rapid path to clinic, which will significantly de-risk our obesity development program.